

REMARKS

Claims 1-50 were pending in the application. Claims 1-50 have been cancelled. New claims 51-81 have been added. Accordingly, after the amendments presented herein have been entered, claims 51-81 will be pending. Support for claims 51-81 can be found throughout the specification and in the claims as originally filed. No new matter has been introduced by way of this preliminary amendment.


In particular, new claims 51-53 are drawn to human antibodies comprising particular complementarity determining regions (CDRs). These CDRs, which are present within the light and heavy chain variable region sequences (SEQ ID NOs: 2, 6, 10 and 4, 8, 12, respectively) of human antibodies 3F2, 1D2 and 2E8, as exemplified in the specification, and were identified using standard CDR mapping techniques well known to those of ordinary skill in the art. Accordingly, the CDRs delineated in new claims 51-53 are an inherent feature, recognizable by one of ordinary skill in the art, of the complete variable region sequences of antibodies 3F2, 1D2 and 2E8, as originally filed in the present application. As such, new claims 51-53 are fully supported by the present specification and do not add new matter.

CONCLUSION

It is respectfully submitted that this application is in condition for allowance. If there are any remaining issues, or the Examiner believes that a telephone conversation with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

  
\_\_\_\_\_  
Jane E. Remillard, Esq.  
Reg. No. 38,872  
Attorney for Applicants

Date: October 7, 2003

Lahive & Cockfield, LLP  
28 State Street  
Boston, Massachusetts 02109  
Telephone: (617) 227-7400  
Facsimile: (617) 742-4214